Combined with TCGA data supporting decreased transcription of immune cell chemotaxis pathways, these data suggest that mutant IDH-driven changes in the tumor-associated immune cell component may contribute to the differential survival times observed in mutant and wild-type glioma patients. This evidence concerns the gene IDH1 and neoplasm.